Skip to main content
. 2023 Aug 25;29(9):2216–2223. doi: 10.1038/s41591-023-02494-2

Extended Data Fig. 2. Individual absolute changes in liver fat content measured using magnetic resonance imaging-proton density fat fraction at Day 71 (A) and Day 168 (B) post dose for participants with hepatic steatosis receiving repeat doses of 200 mg ARO-ANG3 or placebo.

Extended Data Fig. 2

Waterfall plots showing individual absolute changes in liver fat content, measured using magnetic resonance imaging-proton density fat fraction (MRI-PDFF), at post-dose Day 71 (A) and Day 168 (B) for participants with hepatic steatosis receiving repeat doses of 200 mg ARO-ANG3 or receiving placebo.